Compare Aterian Inc (ATER) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aterian Inc vs BIO-TECHNE Corp — how do they compare? Aterian Inc trades at $1.28 (market cap $12.98M), while BIO-TECHNE Corp trades at $71.49 (market cap $11.10B). The key difference: BIO-TECHNE Corp is far larger — about 855.2× Aterian Inc's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Aterian Inc pays none. Which is the better fit depends on your goals.
| ATER | TECH | |
|---|---|---|
Market Cap | $12.98M | $11.10B |
Sector | Consumer Cyclical | Health |
52-Week High | $1.39 | $71.38 |
52-Week Low | $0.54 | $43.31 |
Enterprise Value | $13.56M | $11.18B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aterian (ATER) trades at $1.19, up 3.48% with a bullish technical signal despite negative profitability. Recent earnings beats and a pending asset sale that could return $0.85-$1.14 per share provide near-term catalysts. However, the company shows declining revenue from $221M in 2022 to $69M in 2025, with negative net income margins and cash flow challenges.
The outlook hinges on shareholder approval of the brand portfolio sale, offering potential shareholder returns near current price levels. Investment opportunity exists in the asset sale catalyst, but risks include ongoing operational losses, declining revenue, and negative cash flow. Analyst sentiment is evenly split between Buy and Hold recommendations.
Bio-Techne (TECH) trades at $71.36, showing minimal daily movement (+0.08%) as the market digests Merck KGaA's $73 per share acquisition offer. The stock sits just 2.3% below the buyout price, with technical indicators showing bullish momentum. Fundamentally, the company maintains strong gross margins (64.96%) but faces declining net income margins (6.01% in 2025). Recent earnings show mixed results with one beat and two misses in the last four quarters.
The acquisition premium provides near-term upside potential, though shareholder litigation risks exist regarding deal fairness. Long-term investors face uncertainty about post-acquisition prospects, while current valuation metrics (P/E 101.94) appear stretched without the takeover scenario. The $73 offer price represents the primary catalyst, with downside risk to $50 if the deal fails.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aterian Inc
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products, and consumer electronics. It has various owned and operated brands include Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. The company generates revenue through the online sales of various consumer products that are sold online.
Read more on ATER →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
